Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

Yoshiharu Motoo; Yasuto Tomita; Hideto Fujita

doi:10.1007/s10147-020-01648-3

Prophylactic efficacy of ninjin’yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2)

International Journal of Clinical Oncology ◽

10.1007/s10147-020-01648-3 ◽

2020 ◽

Vol 25 (6) ◽

pp. 1123-1129

Author(s):

Yoshiharu Motoo ◽

Yasuto Tomita ◽

Hideto Fujita

Keyword(s):

Colorectal Cancer ◽

Peripheral Neuropathy ◽

Adjuvant Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Postoperative Adjuvant Chemotherapy ◽

Prophylactic Efficacy ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30041-x ◽

2019 ◽

Vol 4 (5) ◽

pp. 376-388 ◽

Cited By ~ 8

Author(s):

Stine Braendegaard Winther ◽

Gabor Liposits ◽

Halla Skuladottir ◽

Eva Hofsli ◽

Carl-Henrik Shah ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Combination Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Reduced Dose ◽

Phase 2 Trial ◽

Vulnerable Patients ◽

Open Label Phase ◽

Dose Combination

Download Full-text

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3652 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3652-TPS3652

Author(s):

Johanna C. Bendell ◽

Benjamin R. Tan ◽

James Andrew Reeves ◽

Henry Q. Xiong ◽

Rita Laeufle ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00150-9 ◽

2016 ◽

Vol 17 (6) ◽

pp. 738-746 ◽

Cited By ~ 362

Author(s):

Andrea Sartore-Bianchi ◽

Livio Trusolino ◽

Cosimo Martino ◽

Katia Bencardino ◽

Sara Lonardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Proof Of Concept ◽

Wild Type ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Treatment Refractory ◽

Kras Codon

Download Full-text

Faculty Opinions recommendation of Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726308902.793550903 ◽

2018 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Proof Of Concept ◽

Wild Type ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Treatment Refractory ◽

Kras Codon

Download Full-text

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(20)30362-3 ◽

2021 ◽

Cited By ~ 2

Author(s):

Cornedine J de Gooijer ◽

Vincent van der Noort ◽

Jos A Stigt ◽

Paul Baas ◽

Bonne Biesma ◽

...

Keyword(s):

Malignant Mesothelioma ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Line Chemotherapy

Download Full-text

Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00030-2 ◽

2021 ◽

Vol 8 (4) ◽

pp. e289-e298 ◽

Cited By ~ 1

Author(s):

Lu Sun ◽

Juan Wang ◽

Linlin Shao ◽

Chenglu Yuan ◽

Hongguo Zhao ◽

...

Keyword(s):

Immune Thrombocytopenia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Primary Immune Thrombocytopenia ◽

Open Label Phase ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739562946.793583755 ◽

2021 ◽

Author(s):

Patrick Richard

Keyword(s):

Prostate Cancer ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Phase 2 Trial ◽

Castration Resistant ◽

Open Label Phase

Download Full-text

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

The Lancet ◽

10.1016/s0140-6736(14)61795-5 ◽

2015 ◽

Vol 385 (9973) ◽

pp. 1075-1086 ◽

Cited By ~ 208

Author(s):

Eric Lawitz ◽

Edward Gane ◽

Brian Pearlman ◽

Edward Tam ◽

Wayne Ghesquiere ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Phase 2 ◽

Efficacy And Safety ◽

Genotype 1 ◽

Virus Genotype ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Null Response

Download Full-text

Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(18)30480-8 ◽

2019 ◽

Vol 19 (1) ◽

pp. 46-55 ◽

Cited By ~ 9

Author(s):

Jung-Kyu Lee ◽

Ji Yeon Lee ◽

Deog Kyeom Kim ◽

Ho Il Yoon ◽

Ina Jeong ◽

...

Keyword(s):

Pulmonary Tuberculosis ◽

Phase 2 ◽

Open Label ◽

Intensive Phase ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text